Business
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors
-- XmAb20717 generally well-tolerated and a confirmed complete response (CR) observed at highest dose level tested -- -- Robust, dose-dependent immune
About this update from Xencor, Inc.
[{"type":"text","content":"\n-- XmAb20717 generally well-tolerated and a confirmed complete response (CR) observed at highest dose level tested --\n\n\n-- Robust, dose-dependent immune activation consistent with inhibition of both PD-1 and CTLA-4 checkpoints --\n\n\n-- Further dose-escalation and expansion cohorts continue to enroll patients with advanced solid tumors --\n\n MONROVIA, Calif.--(BUSINESS WIRE)--\nXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported initial dose-escalation data from the Phase 1 study evaluating XmAb®20717, a PD-1 x CTLA-4 bispecific antibody and Xencor’s first tumor microenvironment activator, in patients with advanced solid tumors (DUET-2). The American Society of Clinical Oncology (ASCO) has published an abstract (e15001) with initial clinical data from the study on its website today.\n\n\n“In our first six dose-escalation cohorts, we observed XmAb20717 to be generally well-tolerated in heavily pretreated patients with advanced solid tumors. We observed dose-dependent increases in T-cell activation biomarkers, and from the cohort of seven patients receiving the highest dose of 10 mg/kg, we are encouraged that a patient with melanoma, who was treated previously with prior checkpoint therapy, achieved a confirmed complete response. Based on these data and to further characterize safety and activity, we opened expansion cohorts in several tumor types at 10 mg/kg. Also, we did not reach a maximum tolerated dose and expanded the study to enroll patients into additional escalation cohorts, currently at 15 mg/kg and potentially at 20 mg/kg dose levels, and the possibility remains to modify the expansion cohorts with higher dosing,” said Allen Yang, M.D., Ph.D., senior vice president and chief medical officer at Xencor.\n\n\n“We tuned XmAb20717’s affinities for PD-1 and CTLA-4 for selective engagement of T cells expressing both targets, and we see pharmacodynamic activity consistent with blockade of both receptors. This design is different from combination therapy and most bispecific checkpoint inhibitors, and we hope to drive improved tolerability at higher doses,” said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. “We look forward to sharing continued progress from the XmAb20...